Skip to Content

Testing in cells is an important and exciting first step. elkor/E+ via Getty Images

Researchers: 47 drugs that might treat the coronavirus

The more researchers know about how the coronavirus attaches, invades and hijacks human cells, the more effective the search for drugs to fight it. That was the idea my colleagues and I hoped to be true when we began building a map of the coronavirus two months ago. The map shows all of the coronavirus proteins and all of the proteins found in the human body that those viral proteins could interact with.

Published: May 3, 2020, 10:58 am

    Nevan Krogan, University of California, San Francisco

    In theory, any intersection on the map between viral and human proteins is a place where drugs could fight the coronavirus. But instead of trying to develop new drugs to work on these points of interaction, we turned to the more than 2,000 unique drugs already approved by the FDA for human use. We believed that somewhere on this long list would be a few drugs or compounds that interact with the very same human proteins as the coronavirus.

    We were right.

    Our multidisciplinary team of researchers at the University of California, San Francisco, called the QCRG, identified 69 existing drugs and compounds with potential to treat COVID-19. A month ago, we began shipping boxes of these drugs off to Institut Pasteur in Paris and Mount Sinai in New York to see if they do in fact fight the coronavirus.


    Every place that a coronavirus protein interacts with a human protein is a potential druggable site.
    QBI Coronavirus Research Group, CC BY-ND

    The testing process

    The map we developed and the FDA drug catalog we screened it against showed that there were potential interactions between the virus, human cells and existing drugs or compounds. But we didn’t know whether the drugs we identified would make a person more resistant to the virus, more susceptible or do anything at all.

    To find those answers we needed three things: the drugs, live virus and cells in which to test them. It would be optimal to test the drugs in infected human cells. However, scientists don’t yet know which human cells work best for studying the coronavirus in the laboratory. Instead we used African green monkey cells, which are frequently used in place of human cells to test antiviral drugs. They can be readily infected with the coronavirus and respond to drugs very closely to the way human cells do.

    After infecting these monkey cells with live virus, our partners in Paris and New York added the drugs we identified to half and kept the other half as controls. They then measured the amount of virus in the samples and the number of cells that were alive. If the samples with drugs had a lower virus count and more cells alive compared to the control, that would suggest the drugs disrupt viral replication. The teams were also looking to see how toxic the drugs were to the cells.

    With dozens of drugs each needing full testing, to get results in four weeks required round-the-clock effort.
    Quantitative Biosciences Institute, CC BY-ND

    After sorting through the results of hundreds of experiments using 47 of the predicted drugs, it seems our interaction predictions were correct. Some of the drugs do in fact work to fight the coronavirus, while others make cells more susceptible to infection.

    It is incredibly important to remember that these are preliminary findings and have not been tested in people. No one should go out and buy these drugs.

    But the results are interesting for two reasons. Not only did we find individual drugs that look promising to fight the coronavirus or may make people more susceptible to it; we know, at a cellular level, why this is happening.

    We identified two groups of drugs that affect the virus and they do it two different ways, one of which has never been described.

    Disrupting translation

    At a basic level, viruses spread by entering a cell, hijacking some of the cell’s machinery and using it to make more copies of the virus. These new viruses then go on to infect other cells. One step of this process involves the cell making new viral proteins out of viral RNA. This is called translation.

    When going through the map, we noticed that several viral proteins interacted with human proteins involved in translation and a number of drugs interacted with these proteins. After testing them, we found two compounds that disrupt the translation of the virus.

    The two compounds are called ternatin-4 and zotatifin. Both of these are currently used to treat multiple myeloma and seem to fight COVID-19 by binding to and inhibiting proteins in the cell that are needed for translation.

    Plitidepsin is a similar molecule to ternatin-4 and is currently undergoing a clinical trial to treat COVID-19. The second drug, zotatifin, hits a different protein involved in translation. We are working with the CEO of the company that produces it to get it into clinical trials as soon as possible.

    The coronavirus attacks human cells using dozens of devious tricks.
    narvikk/iStock Getty Images Plus via Getty Images

    Sigma receptors

    The second group of drugs we identified work in an entirely different way.

    Cell receptors are found both inside of and on the surface of all cells. They act like specialized switches. When a specific molecule binds to a specific receptor, this tells a cell to do a specific task. Viruses often use receptors to infect cells.

    Our original map identified two promising MV cell receptors for drug treatments, SigmaR1 and SigmaR2. Testing confirmed our suspicions.

    We identified seven drugs or molecules that interact with these receptors. Two antipsychotics, haloperidol and melperone, which are used to treat schizophrenia, showed antiviral activity against SARS-CoV-2. Two potent antihistamines, clemastine and cloperastine, also displayed antiviral activity, as did the compound PB28 and the female hormone progesterone.

    Remember, all these interactions have so far only been observed in monkey cells in petri dishes.

    At this time we do not know exactly how the viral proteins manipulate the SigmaR1 and SigmaR2 receptors. We think the virus uses these receptors to help make copies of itself, so decreasing their activity likely inhibits replication and reduces infection.

    Interestingly, a seventh compound – an ingredient commonly found in cough suppressants, called dextromethorphan – does the opposite: Its presence helps the virus. When our partners tested infected cells with this compound, the virus was able to replicate more easily, and more cells died.

    Laboratory testing is excellent at generating leads but clinical trials must be done to know if these findings translate to the real world.
    Quantitative Biosciences Institute, CC BY-ND

    This is potentially a very important finding, but, and I cannot stress this enough, more tests are needed to determine if cough syrup with this ingredient should be avoided by someone who has COVID-19.

    All these findings, while exciting, need to undergo clinical trials before the FDA or anyone else should conclude whether to take or stop taking any of these drugs in response to COVID-19. Neither people nor policymakers nor media outlets should panic and jump to conclusions.

    Another interesting thing to note is that hydroxychloroquine – the controversial drug that has shown mixed results in treating COVID-19 – also binds to the SigmaR1 and SigmaR2 receptors. But based on our experiments in both labs, we do not think hydroxychloroquine binds to them efficiently.

    Researchers have long known that hydroxychloroquine easily binds to receptors in the heart and can cause damage. Because of these differences in binding tendencies, we don’t think hydroxychloroquine is a reliable treatment. Ongoing clinical trials should soon clarify these unknowns.

    Treatment sooner rather than later

    Our idea was that by better understanding how the coronavirus and human bodies interact, we could find treatments among the thousands of drugs and compounds that already exist.

    Our idea worked. We not only found multiple drugs that might fight SARS-CoV-2, we learned how and why.

    But that is not the only thing to be excited about. These same proteins that SARS-CoV-2 uses to infect and replicate in human cells and that are targeted by these drugs are also hijacked by related coronaviruses SARS-1 and MERS. So if any of these drugs do work, they will likely be effective against COVID-22, COVID-24 or any future iterations of COVID that may emerge.

    Are these promising leads going to have any effect?

    The next step is to test these drugs in human trials. We have already started this process and through these trials researchers will examine important factors such as dosage, toxicity and potential beneficial or harmful interactions within the context of COVID-19.

    [The Conversation’s most important coronavirus headlines, weekly in a new science newsletter.]The Conversation

    Nevan Krogan, Professor and Director of Quantitative Biosciences Institute & Senior Investigator at the Gladstone Institutes, University of California, San Francisco

    This article is republished from The Conversation under a Creative Commons license. Read the original article.

    Consider donating to support our work

    Help us to produce more articles like this. FreeWestMedia is depending on donations from our readers to keep going. With your help, we expose the mainstream fake news agenda.

    Keep ​your language polite​. Readers from many different countries visit and contribute to Free West Media and we must therefore obey the rules in​,​ for example​, ​Germany. Illegal content will be deleted.

    If you have been approved to post comments without preview from FWM, you are responsible for violation​s​ of​ any​ law. This means that FWM may be forced to cooperate with authorities in a possible crime investigation.

    If your comments are subject to preview ​by FWM, please be patient. We continually review comments but depending on the time of day it can take up to several hours before your comment is reviewed.

    We reserve the right to del​ete​ comments that are offensive, contain slander or foul language, or are irrelevant to the discussion.


    A country without an honest media is lost

    For some time I have reported to you that in place of a media, a media that our founding fathers relied on to protect our society, the United States has had a propaganda ministry whose sole purpose is to destroy our society.

    Sweden’s decaying democracy

    A journalist is arrested and dragged out of the Gothenburg Book Fair because he politely asked a powerful politician... the wrong questions about his support for the ethnically-cleansed Zimbabwean dictatorship. Not only journalists, but academics and bloggers are being hounded by the leftist establishment daily. And the leftists have all the nasty instruments of the state at their disposal. Citizen reporter Fabian Fjälling looks into their excesses.

    The geopolitical future of Nordic countries

    Between unity and disunity, independence and foreign interference: Nordic countries have to either choose between creating an independent neutral block in the North, or seeing the region being divided between the great powers.

    Russian, Chinese intelligence: ISIS heading for Central Asia with US cover

    Operatives of the crumbling Islamic State in Syria and Iraq (ISIS) are moving to new battlegrounds near the Russian border, intelligence sources have revealed.

    The unraveling of US/Russian relations

    Washington has taken nuclear war against Russia from a hypothetical scenario to a real danger that threatens the future of humanity. 

    Hero commander killed in Syria – when the war is nearly won

    For most Syrians it came as a shock: One of the most popular military commanders of the Syrian Arab Army, Issam Zahreddine, was killed on 18 October 2017.

    What Is The Obama Regime Up To?

    Obama has announced new sanctions on Russia based on unsubstantiated charges by the CIA.

    Kevork Almassian: Aleppo resisted and triumphed

    OPINIONEven the Western Mainstream Media couldn’t hide the celebrations and the joy of the civilians in Aleppo, who expressed their gratitude to the Syrian Army and Russia.

    Lebanon’s new president: Michel Aoun


    Ukrainian Terror and Donbass referendum: What we can learn from the latest events in Donetsk

    OPINIONThe assassination of Donbass field commander Arsen “Motorola” Pavlov on October 16 can be seen as a new escalation of the war scenario in former Eastern Ukraine. The successful elimination of one of the most popular commanders of the independence war of Donbass brought that geopolitical hotspot – despite the events in Syria´s Aleppo – back in Western mainstream media.

    Go to archive